Analysts expect Omnicell Technologies (NASDAQ:OMCL) to report sales of $177.37 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Omnicell Technologies’ earnings, with the highest sales estimate coming in at $177.41 million and the lowest estimate coming in at $177.32 million. Omnicell Technologies reported sales of $150.55 million in the same quarter last year, which indicates a positive year over year growth rate of 17.8%. The firm is expected to issue its next earnings report after the market closes on Thursday, April 26th.

According to Zacks, analysts expect that Omnicell Technologies will report full year sales of $789.37 million for the current fiscal year, with estimates ranging from $788.21 million to $790.51 million. For the next year, analysts anticipate that the firm will report sales of $879.58 million per share, with estimates ranging from $867.46 million to $898.15 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Omnicell Technologies.

Omnicell Technologies (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.02. The business had revenue of $198.26 million during the quarter, compared to the consensus estimate of $205.50 million. Omnicell Technologies had a return on equity of 1.54% and a net margin of 2.88%. Omnicell Technologies’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.37 EPS.

Several equities analysts have commented on the company. Zacks Investment Research upgraded Omnicell Technologies from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 27th. Craig Hallum downgraded Omnicell Technologies from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub downgraded Omnicell Technologies from a “hold” rating to a “sell” rating in a research report on Friday. Cantor Fitzgerald reiterated a “buy” rating and issued a $63.00 target price on shares of Omnicell Technologies in a research report on Tuesday, April 3rd. Finally, Piper Jaffray increased their target price on Omnicell Technologies from $38.00 to $44.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $56.14.

In other news, Chairman Randall A. Lipps sold 8,186 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $44.21, for a total transaction of $361,903.06. Following the completion of the transaction, the chairman now directly owns 224,206 shares in the company, valued at $9,912,147.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Peter J. Kuipers sold 724 shares of the firm’s stock in a transaction dated Thursday, April 12th. The stock was sold at an average price of $46.00, for a total value of $33,304.00. Following the transaction, the insider now owns 56,970 shares of the company’s stock, valued at $2,620,620. The disclosure for this sale can be found here. Insiders sold 20,769 shares of company stock valued at $927,970 over the last quarter. Corporate insiders own 3.71% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of OMCL. Elkfork Partners LLC bought a new position in shares of Omnicell Technologies during the fourth quarter worth about $225,000. Xact Kapitalforvaltning AB bought a new position in shares of Omnicell Technologies during the fourth quarter worth about $244,000. Stone Ridge Asset Management LLC bought a new position in shares of Omnicell Technologies during the fourth quarter worth about $360,000. USA Financial Portformulas Corp bought a new position in shares of Omnicell Technologies during the fourth quarter worth about $364,000. Finally, Shelton Capital Management raised its position in shares of Omnicell Technologies by 17.6% during the fourth quarter. Shelton Capital Management now owns 9,800 shares of the company’s stock worth $475,000 after acquiring an additional 1,464 shares during the last quarter.

Omnicell Technologies stock traded down $0.65 during trading hours on Thursday, hitting $43.15. The stock had a trading volume of 260,523 shares, compared to its average volume of 277,394. The company has a current ratio of 1.73, a quick ratio of 1.28 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $1,682.54, a PE ratio of 243.33, a P/E/G ratio of 3.57 and a beta of 0.74. Omnicell Technologies has a one year low of $38.00 and a one year high of $55.40.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2018/04/24/brokerages-anticipate-omnicell-technologies-omcl-will-post-quarterly-sales-of-177-37-million.html.

Omnicell Technologies Company Profile

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

Get a free copy of the Zacks research report on Omnicell Technologies (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omnicell Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Technologies and related companies with MarketBeat.com's FREE daily email newsletter.